Loading study record…
The randomised controlled study on regulated cannabis access in pharmacies in Basel aims to investigate the effects of regulated cannabis access on consumption behaviour and mental and physical health in comparison to the illegal market.
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.govlast source update 2026-09-02
What this record can show
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
This project consist of two parts: The first part is a randomised controlled study, the second part is an observational study. The randomised controlled study will last six months. Participants will randomly be assigned to one of two groups: Group 1 has immediately access to regulated cannabis in pharmacies; Group 2 has to wait for six months. After six months all participants will have access to regulated cannabis in pharmacies (oberservational study). Every six month participants will be invited to answer online-questionnaires on their cannabis consumption behavior, their mental and physical health. The entire study lasts 2.5 years.
Linked local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Research network
Interventions
The study does not investigate the health effects of cannabis. The study investigates the effects of regulated cannabis access on cannabis consumption and health in comparison to the unregulated illegal market.
Eligibility
primary outcomes
Time frame: 6 / 12 /18 /24 / 30 months
Cannabis Use Disorder Identification Test - Revised; min. value 0, max. value 32; higher scores mean worse outcome
secondary outcomes
Time frame: 6 / 12 /18 /24 / 30 months
Patient Health Questionnaire; min. value 0, max. value 27; higher scores mean worse outcome
Time frame: 6 / 12 /18 /24 / 30months
Generalized Anxiety Disorder; min. value 0, max. value 21; higher scores mean worse outcome
Time frame: 6 / 12 /18 /24 / 30 months
Checklist of early intervention; min. value 0, max. value 8; higher scores mean worse outcome
Time frame: 6 / 12 /18 /24 / 30 months
Symptom Checklist - 90, Somatization; min. value 0, max. value 48; higher scores mean worse outcome
Publications